Jay Cutler and TRT: What Clinicians Should Tell Patients

Who Is Jay Cutler and Why Do Patients Mention Him?

Jay Cutler is a retired professional bodybuilder who won the IFBB Mr. Olympia title four times between 2006 and 2010. He competed at a stage weight of approximately 260 pounds at 5'9", a physique that required decades of training, precise nutrition, and, as Cutler has acknowledged in interviews, performance-enhancing drug use during his competitive years. Since retiring in 2013, Cutler has built a significant media presence through YouTube, podcasts, and social media, where he has discussed his transition from competitive-level hormones to therapeutic TRT.

Why Cutler's Openness Matters in the Clinic

Patients bring up Cutler because he represents a rare category: an elite bodybuilder who speaks candidly about post-career hormone management. In a podcast appearance on the Muscle & Fitness platform, Cutler stated that he uses testosterone and monitors his bloodwork regularly under physician supervision. This kind of public disclosure, while admirable for its honesty, can create misunderstandings. Patients may assume that TRT will produce physiques resembling Cutler's, or that the transition from supraphysiological doses to therapeutic ranges is simple and consequence-free 1.

The Clinical Opportunity

Rather than dismissing the reference, clinicians should treat the mention of Cutler as a valuable opening. It signals that the patient is thinking about hormone optimization, is aware that TRT exists, and may already be researching protocols online. The 2018 Endocrine Society Clinical Practice Guideline for testosterone therapy provides the evidence-based framework for these conversations 1.

Separating Competitive Bodybuilding Pharmacology from Therapeutic TRT

The pharmacological reality of professional bodybuilding bears almost no resemblance to clinical TRT. Patients need to understand this gap clearly, or they will arrive at the clinic with expectations that no responsible provider can meet.

Dose Differences Are Enormous

During competition, elite bodybuilders have reported using testosterone in doses ranging from 500 mg to over 2,000 mg per week, frequently stacked with multiple other anabolic-androgenic steroids (AAS), growth hormone, insulin, and various peptides. A 2014 systematic review in the Journal of Clinical Endocrinology & Metabolism documented that AAS users commonly employed doses 5 to 40 times greater than physiological replacement levels 2. Therapeutic TRT, by contrast, targets a serum testosterone level of 450 to 600 ng/dL, which typically requires 75 to 100 mg of testosterone cypionate or enanthate weekly 1.

What Cutler Has Actually Said

Cutler has stated in multiple interviews that his current protocol is "nothing like" what he used during competition. He has described his approach as physician-supervised, bloodwork-driven, and focused on feeling good rather than maintaining contest-level muscle mass. While Cutler has not disclosed specific dosages publicly, he has emphasized that his current use is a medical decision, not a bodybuilding strategy. Clinicians should note this distinction: even Cutler himself frames post-retirement TRT as health management, not performance enhancement.

The Physique Gap Patients Need to Accept

A 2021 cross-sectional study published in Translational Andrology and Urology found that men initiating TRT gained an average of 3.1 kg of lean mass over 12 months at therapeutic doses 3. That is a meaningful improvement for a hypogonadal man. It is not remotely close to the 40 to 60 pounds of additional muscle mass that separates a professional bodybuilder from a well-trained natural lifter. Patients referencing Cutler's physique need to hear this number early in the consultation.

Clinical Indications: When TRT Is Actually Appropriate

TRT is a medical therapy for diagnosed hypogonadism, not an aesthetic tool. The Endocrine Society's 2018 guidelines establish clear diagnostic criteria that clinicians should follow regardless of what a patient's favorite bodybuilder does 1.

Diagnostic Criteria

Diagnosis requires two morning serum total testosterone measurements below 300 ng/dL (measured by liquid chromatography-tandem mass spectrometry, not immunoassay when possible) combined with signs and symptoms of testosterone deficiency. Symptoms include reduced libido, erectile dysfunction, fatigue, decreased muscle mass, increased body fat, depressed mood, and reduced bone mineral density 1.

Who Should Not Receive TRT

The Endocrine Society explicitly recommends against TRT in men planning fertility within 6 to 12 months (exogenous testosterone suppresses spermatogenesis), men with untreated severe obstructive sleep apnea, men with uncontrolled heart failure, men with a hematocrit above 50%, and men with a recent history of thromboembolism. The American Urological Association's 2018 guideline echoes these contraindications and adds that baseline PSA screening is required before initiation 4.

The FDA's Position

The FDA approved testosterone products only for men with low testosterone caused by specific medical conditions (primary or secondary hypogonadism). In 2015, the FDA issued a required labeling change for all testosterone products warning of a possible increased risk of cardiovascular events, although subsequent data from the TRAVERSE trial (N=5,246) showed no significant increase in major adverse cardiovascular events with testosterone treatment in men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease 5.

The Post-AAS Patient: A Special Clinical Scenario

Patients who reference Jay Cutler may themselves have a history of anabolic steroid use. This creates a distinct clinical presentation that requires specific management.

Hypothalamic-Pituitary-Gonadal Axis Suppression

Prolonged AAS use suppresses the HPG axis. A 2019 study in the Journal of the Endocrine Society found that among 100 former AAS users, 56% had testosterone levels below 300 ng/dL more than three months after cessation 6. Recovery can take 3 to 12 months in mild cases but may be permanent after years of high-dose use. These patients may genuinely need lifelong TRT, making their clinical situation closer to Cutler's than they initially realize.

Evaluating the Former User

For patients who disclose prior AAS use, clinicians should obtain a full hormone panel including total testosterone, free testosterone, LH, FSH, estradiol, SHBG, prolactin, and a complete metabolic panel. LH and FSH levels are the key discriminators. Low LH and FSH with low testosterone suggest central (secondary) hypogonadism consistent with ongoing HPG suppression. Normal or elevated LH/FSH with low testosterone may indicate primary testicular failure, which can also result from long-term AAS toxicity 6.

Recovery Attempts Before Committing to TRT

For patients who ceased AAS within the past 6 to 12 months, a trial of observation or selective estrogen receptor modulator (SERM) therapy with clomiphene citrate (25 to 50 mg daily) may restore endogenous production. A 2020 retrospective analysis in Urology found that 68% of former AAS users treated with clomiphene achieved testosterone levels above 400 ng/dL within 3 months 7. If recovery does not occur after 6 months, long-term TRT becomes reasonable.

Monitoring Protocols That Protect Patient Safety

The 2018 Endocrine Society guideline outlines a monitoring schedule that clinicians must follow for every TRT patient. Jay Cutler has mentioned getting regular bloodwork, which is exactly the right message for patients to hear, but the specifics matter.

Baseline and Follow-Up Labs

Before starting TRT, obtain: total testosterone (two morning draws), complete blood count with hematocrit, PSA, lipid panel, hepatic function panel, and a metabolic panel including fasting glucose. The first follow-up labs should occur at 3 to 6 months after initiation, then every 6 to 12 months thereafter 1.

Hematocrit: The Most Common Safety Concern

Testosterone stimulates erythropoiesis. Hematocrit elevations above 54% require dose reduction or temporary cessation and possible phlebotomy. A 2017 pharmacovigilance study in JAMA Internal Medicine found that TRT-associated polycythemia occurred in 5.5% of treated men, with risk increasing in older patients and those using injectable formulations versus gels 8.

PSA and Prostate Monitoring

The TRAVERSE trial's prostate safety substudy found no significant difference in prostate cancer incidence between testosterone and placebo groups over a median follow-up of 33 months 5. The Endocrine Society recommends checking PSA at 3 to 6 months, then annually. A PSA rise of more than 1.4 ng/mL within any 12-month period or an absolute PSA above 4.0 ng/mL warrants urology referral 1.

Cardiovascular Monitoring

The TRAVERSE trial (N=5,246, published in the New England Journal of Medicine in 2023) demonstrated that testosterone replacement in men aged 45 to 80 with hypogonadism and established or high cardiovascular risk did not increase the incidence of major adverse cardiovascular events (HR 0.99; 95% CI 0.81 to 1.21) over a mean follow-up of 21.7 months 5. This is the largest and most definitive trial on TRT cardiovascular safety to date. Clinicians can share this data with patients who express concern.

Counseling Framework: What to Say When a Patient Mentions Jay Cutler

Clinicians benefit from a structured response when patients bring up celebrity TRT use. The following framework moves the conversation from pop culture to evidence without dismissing the patient's interest.

Step 1: Acknowledge and Validate

"It's good that you're thinking about hormone health. Jay Cutler has been open about his use of TRT after retirement, and that kind of transparency helps reduce stigma." This validates the patient's research without endorsing the specifics.

Step 2: Establish the Medical Threshold

"TRT is a medical treatment for men with documented low testosterone. We need to measure your levels first. If your testosterone is below 300 ng/dL on two separate morning blood draws and you have symptoms, you may be a candidate." The Endocrine Society's diagnostic threshold is the anchor point 1.

Step 3: Set Realistic Expectations

"Therapeutic testosterone doses are designed to bring your levels into the normal range, typically 450 to 600 ng/dL. At these levels, men with true hypogonadism see improvements in energy, mood, libido, and modest gains in lean mass. You will not look like a professional bodybuilder from TRT alone." The 2016 Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies involving 790 men aged 65 and older with testosterone below 275 ng/dL, showed improvements in sexual function, walking distance, and mood, but physical function gains were modest 9.

Step 4: Discuss Risks Honestly

"TRT can increase red blood cell count, which raises stroke and clot risk if hematocrit gets too high. It will suppress your sperm production. Some men develop acne or worsened sleep apnea. These are manageable with monitoring, but they are real." Providing specific risk data builds trust. The AUA guideline notes that patients must understand fertility implications before starting 4.

Step 5: Define the Monitoring Commitment

"If we start TRT, you're committing to regular blood work: at 3 months, 6 months, and then at least annually. We check your hematocrit, PSA, lipids, and testosterone trough level every time." Framing monitoring as a non-negotiable part of the prescription prevents downstream adherence problems.

Formulation Options and Practical Considerations

Patients influenced by bodybuilding culture typically expect injectable testosterone. Clinicians should review all available formulations so the patient can make an informed choice.

Injectable Testosterone Cypionate and Enanthate

These remain the most prescribed TRT formulations. Standard dosing is 100 to 200 mg every 1 to 2 weeks, although weekly or twice-weekly dosing produces more stable serum levels and fewer symptomatic troughs 1. Injectables are cost-effective, with generic testosterone cypionate available for as little as $30 to $60 per month without insurance.

Transdermal Gels and Patches

Testosterone gel (AndroGel, Testim, or generic 1% gel) delivers 50 to 100 mg daily and avoids injection-related peaks and troughs. The main concern is transference risk to partners and children through skin contact 1. Patches (Androderm) are another option but carry higher rates of skin irritation.

Oral and Nasal Formulations

Jatenzo (oral testosterone undecanoate) was FDA-approved in 2019 and bypasses first-pass hepatotoxicity through lymphatic absorption. Natesto (nasal testosterone gel) is applied intranasally two to three times daily and may suppress spermatogenesis less than other formulations, although fertility preservation data remains limited 10.

Pellets

Subcutaneous testosterone pellets (Testopel) are implanted every 3 to 6 months. They offer convenience but require an in-office procedure and carry risks of pellet extrusion (8 to 12% in some series) and infection 1.

The Fertility Conversation: A Non-Negotiable Discussion Point

Exogenous testosterone suppresses gonadotropin secretion, which suppresses spermatogenesis. The AUA guideline states: "Testosterone therapy should not be initiated in men desiring fertility" 4. This is one of the most important counseling points for younger patients interested in TRT.

Recovery of spermatogenesis after TRT cessation is variable. A 2019 meta-analysis in Fertility and Sterility found that 67% of men recovered sperm in the ejaculate within 6 months of stopping testosterone, and 90% within 12 months, but recovery was not guaranteed, particularly in men over 40 or those who used testosterone for prolonged periods 11. For men who want both testosterone optimization and preserved fertility, clomiphene citrate or human chorionic gonadotropin (hCG) are evidence-supported alternatives.

What Jay Cutler Gets Right (and What Clinicians Can Reinforce)

Cutler has consistently communicated several messages that align with clinical best practices: that his post-retirement hormone use is physician-supervised, that regular bloodwork is non-negotiable, and that his current doses are far lower than what he used during competition. These are precisely the messages clinicians should reinforce. Where Cutler's public statements fall short is in the specifics: he has not disclosed doses, specific medications, or detailed lab values, which leaves room for patient speculation.

The clinician's role is to fill that gap with data. When a patient says "I want to do what Jay Cutler does," the evidence-based response is: "Let's find out what your body actually needs first."

Prescribe therapeutic TRT at the lowest dose that resolves symptoms, monitor labs on the Endocrine Society's recommended schedule, and revisit the plan every 6 to 12 months.